98%
921
2 minutes
20
Background: Little is known about quality of life (QOL) at the time of multiple sclerosis (MS) or clinically isolated syndrome (CIS) diagnosis and how it evolves in the critical adjustment period immediately following a new diagnosis.
Objectives: To (1) describe QOL trajectory in the first year post-MS/CIS diagnosis and (2) examine associations of demographic and biopsychosocial factors with QOL at baseline and as it evolves over the first year post-MS/CIS diagnosis.
Methods: Participants were N = 250 individuals newly diagnosed with MS or CIS. Participants completed self-report assessments of QOL, demographics, and biopsychosocial factors at 1, 2, 3, 6, 9, and 12 months post-diagnosis using validated measures.
Results: At 1-month post-diagnosis, QOL M = 75.2/100 with subsequent assessments revealing consistent ratings on average. Modelling revealed a small number of variables that were predictive of QOL at baseline and/or change in QOL over time.
Conclusion: QOL in the first year post-MS/CIS diagnosis was, on average, high and stable. A subset of modifiable factors across the biopsychosocial spectrum was associated with baseline level of QOL and change in QOL over time. The stability in QOL suggests that patients can be assessed early after diagnosis for key variables that are predictive of both current and future QOL.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00415-021-10842-w | DOI Listing |
Scand J Med Sci Sports
September 2025
Department of Dermatology and Allergy Biederstein, School of Medicine and Health, TUM University Hospital Rechts der Isar, Munich, Germany.
In wheat allergy dependent on augmentation factors (WALDA), allergic reactions occur when wheat ingestion is combined with exercise or rarely other augmentation factors. We analyzed clinical characteristics and disease burden in recreationally active and trained individuals with WALDA diagnosed by oral challenge test. Clinical characteristics, serological data, and quality of life (QOL) questionnaires were analyzed and completed with follow-up interviews.
View Article and Find Full Text PDFFront Oncol
August 2025
Health Management Department, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: Lung cancer remains a leading cause of cancer-related morbidity and mortality worldwide. As systemic therapy prolongs survival, improving patients' quality of life (QoL) has become a central goal of holistic care. Personalized nursing interventions, tailored to individual patient needs, have shown promise in oncology but lack large-scale evaluation in lung cancer populations.
View Article and Find Full Text PDFAlpha Psychiatry
August 2025
Unit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, University of Macau, Taipa, Macao, China.
Background: Depression is common among older adults with cataracts and is associated with significant functional impairment. However, the complex interrelationships among different depression symptoms are often overlooked by conventional mood disorders research based on total scores of depression measures. This study examined the interrelationships between different depressive symptoms and quality of life (QoL) in older adults with cataracts based on a national survey.
View Article and Find Full Text PDFHIV Med
September 2025
Department of Dermatology, University of Kwa-Zulu Natal, Durban, South Africa.
Introduction: Quality of life (QOL) is an essential component of care in people with HIV-associated Kaposi sarcoma (HIV-KS). Kaposi sarcoma herpes virus (KSHV) promotes cytokine expression and a dysfunctional inflammatory environment, contributing to KS pathogenesis and progression. However, disease-related inflammatory factors influencing QOL and symptoms remain underexplored.
View Article and Find Full Text PDFJ Urol
September 2025
Department of Urology, Albany Medical Center, Albany, NY.
Purpose: Patient-reported outcome measures (PROMs) play a pivotal role when recommending medical interventions. There is a lack of prospective studies directly comparing PROMs following transrectal (TR-Bx) and transperineal prostate biopsy (TP-Bx). We conducted a pre-specified comparative analysis of PROMs from the ProBE-PC randomized trial.
View Article and Find Full Text PDF